A cheaper path to treating diseases that demand lifelong care
In the closing days of September, a European regulatory body moved to widen the circle of care for millions living with chronic inflammatory disease — recommending approval of Gobivaz, a biosimilar to the biologic golimumab, developed by Iceland's Alvotech and set to be commercialized across Europe by Advanz Pharma. The decision, still awaiting formal confirmation from the European Commission, reflects a quiet but consequential shift in modern medicine: as patents on complex biologic therapies expire, their more affordable counterparts are becoming instruments of both economic relief and expanded human access. For patients managing rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or ulcerative colitis — conditions that rarely relent — this recommendation is a step toward a future where effective treatment is less a matter of geography or wealth.
- Millions of Europeans living with chronic inflammatory diseases face lifelong treatment costs that biosimilars like Gobivaz could meaningfully reduce.
- The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for Gobivaz, covering four major inflammatory conditions and two dosage formulations.
- Alvotech's path to this moment required years of clinical work, including a 2023 pharmacokinetic study and a 2024 confirmatory trial in rheumatoid arthritis patients that validated the biosimilar's safety and efficacy against the original drug.
- Advanz Pharma holds exclusive commercialization rights across Europe, the UK, Switzerland, Canada, Australia, and New Zealand — a partnership model designed to move the science from lab to patient at scale.
- The final European Commission marketing authorization decision is still pending, but approval would open access to a lower-cost golimumab alternative across 30 European nations.
On a Monday in late September, a European regulatory committee took a step that could reshape treatment options for millions of people living with chronic inflammatory diseases. The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval for Gobivaz — a biosimilar of Simponi, the biologic golimumab — for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The recommendation emerged from a partnership between Alvotech, an Iceland-based biotech, and Advanz Pharma, headquartered in London.
Biosimilars work much like generics do for traditional pharmaceuticals: they replicate the mechanism of a biologic drug — in this case, blocking tumor necrosis factor alpha to calm the immune system's attack on the body's own tissues — at a lower cost. Gobivaz would be available in two formulations and, if approved, accessible across all 27 EU member states plus Norway, Iceland, and Liechtenstein. Advanz Pharma holds exclusive commercialization rights across an even wider geography, including the UK, Switzerland, Canada, Australia, and New Zealand.
The road to this recommendation was built on clinical evidence. In late 2023, Alvotech published positive pharmacokinetic data from healthy volunteers, and in April 2024, a confirmatory trial in patients with moderate to severe rheumatoid arthritis demonstrated comparable efficacy, safety, and immunogenicity to the reference drug. Those results gave the regulatory committee the foundation it needed.
What remains is procedural: the European Commission must issue a final marketing authorization decision, which typically follows the committee's recommendation. For patients and healthcare systems alike, approval would mean a more affordable path to a class of therapy that often requires lifelong management. For Alvotech — which has eight additional biosimilar candidates in development — and for Advanz Pharma, it would mark a significant milestone in a broader strategy to reshape how biologic medicines reach the people who need them.
On a Monday in late September, a regulatory committee in Europe took a step that could reshape treatment options for millions of people living with chronic inflammatory diseases. The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval for Gobivaz, a biosimilar version of Simponi, a biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The recommendation came from Alvotech, an Iceland-based biotech company, working in partnership with Advanz Pharma, a London-headquartered pharmaceutical firm.
Biosimilars are copies of biologic drugs—medicines made from living cells rather than chemicals—that work much like generic drugs do for traditional pharmaceuticals. They are cheaper to produce than the originals, and when approved, they can significantly reduce the cost burden on healthcare systems and patients. Gobivaz is designed to mimic golimumab, the active ingredient in Simponi, which works by blocking tumor necrosis factor alpha, a protein involved in inflammatory responses. By inhibiting this protein, the drug helps control the immune system's overactive attack on the body's own tissues.
The committee's recommendation covers two formulations: a 50 milligram dose in a 0.5 milliliter pre-filled syringe and a 100 milligram dose in a pre-filled autoinjector. If approved, Gobivaz would be available across the 27 European Union member states, plus Norway, Iceland, and Liechtenstein. This geographic reach matters because it means patients in a large swath of Europe could potentially access a more affordable treatment option for conditions that often require lifelong management.
Alvotech developed the drug and will handle its manufacture and supply. Advanz Pharma secured the exclusive right to register and commercialize Gobivaz throughout Europe, the UK, Switzerland, Canada, Australia, and New Zealand. The partnership reflects a common strategy in the pharmaceutical industry: a smaller biotech company develops the science, while a larger firm with established distribution networks and regulatory relationships brings the product to market. Joseph McClellan, Alvotech's Chief Scientific and Technical Officer, framed the moment as an opportunity to increase patient access to an important treatment. Nick Warwick, Chief Medical Officer at Advanz Pharma, called the positive opinion a significant milestone in building the company's biosimilars presence in Europe.
The path to this recommendation involved rigorous clinical testing. In November 2023, Alvotech published positive results from a pharmacokinetic study comparing AVT05—the internal name for the biosimilar—to Simponi in healthy adult volunteers. That study assessed how the drug moves through the body, its safety profile, and how well it was tolerated. Then, in April 2024, the company announced positive results from a confirmatory clinical trial in patients with moderate to severe rheumatoid arthritis, comparing the biosimilar's efficacy, safety, and immunogenicity directly against the reference drug. These studies provided the evidence base the regulatory committee needed to make its recommendation.
What happens next is procedural but consequential. The European Commission must issue a final decision on whether to grant marketing authorization. That decision typically follows the committee's recommendation, though it is not automatic. Once approved, Gobivaz would enter a market where biosimilars have already begun to reshape treatment economics. For patients and healthcare systems in Europe, the availability of a lower-cost alternative to Simponi could mean more people can access this class of therapy, or that resources can be redirected to other pressing medical needs. For Alvotech and Advanz Pharma, approval would validate years of development work and open a revenue stream in one of the world's most regulated and competitive pharmaceutical markets.
The recommendation also reflects a broader shift in how biologic medicines are being managed globally. As patents on blockbuster biologics expire, biosimilars are becoming a standard tool for controlling healthcare costs while maintaining access to effective treatments. Alvotech has eight other biosimilar candidates in development targeting autoimmune disorders, eye diseases, osteoporosis, respiratory conditions, and cancer. The company has built a network of commercial partnerships across the United States, Europe, Japan, China, and other regions. The Gobivaz approval, pending final European Commission sign-off, represents one milestone in that larger strategy.
Notable Quotes
The positive CHMP opinion marks a significant step forward in expanding patient access and building a leading biosimilars presence in Europe.— Nick Warwick, Chief Medical Officer, Advanz Pharma
We look forward to working with Advanz Pharma to increase access for patients and healthcare professionals to golimumab.— Joseph McClellan, Chief Scientific and Technical Officer, Alvotech
The Hearth Conversation Another angle on the story
Why does a biosimilar matter more than just another drug approval?
Because it's about cost and access. Simponi works well for inflammatory diseases, but it's expensive. A biosimilar that does the same job for less money means more patients can actually afford the treatment, and healthcare systems can stretch their budgets further.
How confident should we be that this biosimilar will work the same way as the original?
The clinical trials tested that directly. They compared the biosimilar to Simponi in real patients with rheumatoid arthritis and in healthy volunteers. The data showed equivalent efficacy and safety. That's why the regulatory committee felt comfortable recommending it.
What's the timeline now?
The European Commission still needs to make the final decision, but that typically follows the committee's recommendation. Once approved, Advanz Pharma will handle getting it into European pharmacies and hospitals. We're probably looking at months, not years, before patients can actually access it.
Who benefits most from this approval?
Patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis across Europe. Also healthcare systems that have been paying premium prices for Simponi. And Alvotech and Advanz Pharma, obviously—this is a commercial win for them.
Is there any risk that a biosimilar won't perform identically to the original?
Theoretically, yes. Biosimilars are complex molecules made in living cells, so there's always some variability. But the regulatory bar is high—the drug has to demonstrate comparable quality, safety, and efficacy. The committee wouldn't have recommended approval if the data didn't support that.
What does this say about the future of expensive biologic drugs?
That their days as monopoly-priced treatments are numbered. As patents expire, biosimilars will compete on cost. It's the same dynamic that happened with generic drugs decades ago, just playing out in a more complex space.